Lance Harmon, MD
Family Medicine · Farmington, NMNPI 1811912157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$498
- Boehringer Ingelheim$471
- Astellas Pharma US Inc$406
- Lilly USA, LLC$370
- Johnson & Johnson$313
- AbbVie$257
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,55897%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $498 |
| Boehringer Ingelheim | 21 | $471 |
| Astellas Pharma US Inc | 15 | $406 |
| Lilly USA, LLC | 19 | $370 |
| Johnson & Johnson | 16 | $313 |
| AbbVie(2 entities) | 13 | $257 |
| Pfizer | 12 | $206 |
| Novo Nordisk | 12 | $189 |
| Amgen | 7 | $164 |
| Amarin Pharma, Inc. | 6 | $133 |
| Merck | 6 | $108 |
| GSK | 5 | $76 |
| Insulet Corporation | 3 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Lundbeck LLC | 2 | $46 |
| Mylan Specialty L.p. | 2 | $43 |
| Exact Sciences | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Novartis | 1 | $20 |
| Dexcom, Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Medtronic | 1 | $14 |
| Gilead | 1 | $12 |
How this compares
$3,658 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 68 | $93,117 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $48,764 |
| JanuviaSitagliptin Phosphate | 21 | $30,035 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $29,924 |
| EliquisApixaban | 36 | $29,248 |
| XareltoRivaroxaban | 30 | $26,591 |
| TrulicityDulaglutide | 11 | $23,946 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $22,699 |
| JardianceEmpagliflozin | 17 | $20,308 |
| FarxigaDapagliflozin Propanediol | 12 | $11,055 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 35 | $10,981 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $9,471 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 39 | $8,674 |
| Levemir FlexpenInsulin Detemir | 17 | $7,781 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $7,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $370 | $117,06379 claims |
| MerckJanuvia | $108 | $30,03521 claims |
| PfizerEliquis | $206 | $29,24836 claims |
| GSKArexvy, Shingrix, Incruse Ellipta | $76 | $26,84195 claims |
| Johnson & JohnsonXarelto | $313 | $26,59130 claims |
| Boehringer IngelheimJardiance | $471 | $20,30817 claims |
| AstraZenecaFarxiga | $498 | $11,05512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Farmington
- Harold McFarlingFarmington$160K
- Joseph HakesFarmington$3K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Wendy JohnsonSanta Fe$37K
- Delliah StamppLas Cruces$21K
- Conchita PazLas Cruces$16K
- Sergio HuertaLas Cruces$11K
- Timothy GrenemyerAlbuquerque$10K
- Cheri BlackstenAlbuquerque$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.